What Is a PDUFA Date? Complete Guide for Biotech Investors
Quick Definition
A PDUFA date is the target action date by which the FDA must issue a decision on a drug application (NDA or BLA). It represents a commitment from the FDA under the Prescription Drug User Fee Act to review applications within specific timeframes. For investors, PDUFA dates are major binary events that can move biotech stocks 30–70% in either direction.
PDUFA Date Definition: The Foundation
The Prescription Drug User Fee Act (PDUFA), enacted in 1992, fundamentally changed how the FDA funds drug reviews. Instead of relying solely on taxpayer funding, pharmaceutical companies pay user fees to accelerate the review process. In exchange, the FDA commits to reviewing drug applications within defined timeframes and assigns a target decision date called the PDUFA date.
A PDUFA date is simply the deadline by which the FDA must issue a decision on a New Drug Application (NDA) for small-molecule drugs or a Biologics License Application (BLA) for biological products. This date isn't arbitrary—it's calculated from the moment FDA formally accepts the application for review.
The review timeline depends on the review type:
- Standard Review: 10–12 months from acceptance. The FDA reviews the application thoroughly but without priority designation.
- Priority Review: 6–8 months from acceptance. Used for drugs addressing unmet medical needs or offering significant advantages over existing therapies.
At the PDUFA date, the FDA can approve the drug (sending it to market), issue a Complete Response Letter (CRL) requesting additional data, or in rare cases extend the review by requesting more information.
How the FDA Sets PDUFA Dates
Understanding how PDUFA dates are calculated helps investors predict timing and plan accordingly.
When a pharmaceutical company submits an NDA or BLA, the FDA has 60 days to decide whether to "accept" the application for review or refuse it (if it's incomplete or missing critical data). This 60-day period is called the pre-review window. Most applications are accepted; refusals are uncommon for well-prepared submissions.
Once the FDA accepts the application (formally known as the "date of receipt" or acceptance date), the review clock starts. For a standard review, the PDUFA date is set 10 months after acceptance. For a Priority Review drug, it's 6 months after acceptance. The company receives written confirmation of the PDUFA date in the FDA's acceptance letter.
If the FDA determines during review that it needs additional information—such as more clinical data, manufacturing details, or responses to specific questions—they issue an "information request" or request for additional information (AI). In these cases, the PDUFA clock can extend by up to 3 months, pushing the date further out. Major amendments submitted by the company can also trigger extensions.
This predictability is valuable for investors: once an application is accepted, you can mark your calendar with the expected PDUFA date several months in advance.
Why PDUFA Dates Matter for Investors
For biotech investors and traders, PDUFA dates represent one of the most significant binary events in the market. The reason: the outcome is genuinely uncertain, the timeline is known in advance, and the impact on stock price is often dramatic.
Approval Rates and Magnitude of Moves: Historical analysis across 2,210 PDUFA events shows an overall approval rate of approximately 68%. However, this varies significantly by therapeutic area, indication, and application type. When a drug is approved, biotech stocks commonly surge 20–50% in a single trading session. Conversely, a Complete Response Letter can trigger a 30–70% decline, wiping out months of gains or destroying shareholder value.
The Runup Phenomenon: Investors and fund managers are well aware of upcoming PDUFA dates. Studies show that biotech stocks often appreciate significantly in the 25 to 5 trading days before the decision (the "runup" period). This reflects a combination of investor optimism, options market positioning, and fund flows in anticipation of binary events. Understanding and trading the runup is a core strategy for event-driven investors. For more on this strategy, see our detailed guide to PDUFA runup trading.
Implied Volatility Expansion: As a PDUFA date approaches, options implied volatility (IV) typically expands. This makes buying options more expensive but selling options more profitable. Sophisticated traders use PDUFA dates to structure vol-based strategies.
Market Catalysts: For smaller biotech companies, a single PDUFA approval can be transformational—converting a development-stage firm into a profitable commercial company. For larger companies, multiple PDUFA dates across a pipeline can create a steady stream of news-driven price movements.
Types of FDA Decisions
At the PDUFA date, the FDA issues one of three primary decisions:
Approval (Gold Standard)
The drug is approved and cleared for marketing. The company can immediately begin commercialization. Stock prices typically spike on approval news.
Complete Response Letter (CRL)
The FDA cannot approve the drug in its current form and cites specific deficiencies. The company must address these points—which may require additional clinical trials, manufacturing changes, or data analysis—and resubmit. A CRL typically triggers a significant stock decline, though the severity depends on the perceived difficulty of addressing FDA's concerns.
Delay / Extension
The FDA determines it needs more time and formally extends the PDUFA date, usually by 3 months. This occurs when major information requests are issued late in the review cycle. Extensions can be both positive (FDA is seriously considering approval but wants more data) and negative (FDA identified major issues), depending on context.
How ODIN Scores PDUFA Catalysts
Predicting FDA decisions is notoriously difficult, but data-driven models can significantly improve odds.ODIN (the Outcome Determination Intelligence Network)is a machine-learning model trained on historical PDUFA outcomes to estimate approval probability for upcoming decisions.
ODIN analyzes 45 featureed signals—including clinical trial efficacy, safety profile, competitive landscape, regulatory precedent, unmet medical need, and FDA feedback history—to predict approval likelihood. Every upcoming PDUFA on the PDUFA.bio calendar is scored by ODIN and assigned to one of four tiers:
- TIER_1: 85% or higher approval probability. High-confidence approvals.
- TIER_2: 65–85% approval probability. Likely approvals with some risk.
- TIER_3: 40–65% approval probability. Toss-ups; genuine uncertainty.
- TIER_4: Below 40% approval probability. Risky applications; CRL more likely than approval.
For the full methodology behind ODIN and how it's trained on historical data, see our detailed ODIN documentation. You can also review ODIN's historical track recordto see how accurate the model has been.
Trading PDUFA Dates: The Runup Strategy
One of the most observed patterns in biotech markets is the PDUFA runup—the tendency for stocks to appreciate in the weeks leading up to an FDA decision, particularly in the 25 to 5 trading days before the PDUFA date.
This occurs for several reasons: retail and institutional investors build positions ahead of perceived "good" outcomes, large funds hedge their existing short positions or buy calls, options dealers need to hedge long gamma exposure, and positive sentiment cascades as more investors become aware of the upcoming catalyst.
Event-driven traders exploit the runup by buying into the anticipation, then selling (or hedging) ahead of the actual decision to capture gains and avoid binary risk. The most successful runup traders combine ODIN probability estimates with technical analysis and options positioning to time entries and exits.
For a comprehensive guide to runup strategies, including case studies and tactical entry/exit rules, see our dedicated PDUFA Runup Trading guide.
Frequently Asked Questions
What does PDUFA stand for?
PDUFA stands for the Prescription Drug User Fee Act. Enacted in 1992, this law established a framework where pharmaceutical companies pay user fees to the FDA in exchange for faster drug review timelines and guaranteed decision dates.
Can the FDA decide before the PDUFA date?
Yes, early approvals are common, especially for Priority Review drugs. The PDUFA date is a target deadline, not a guaranteed decision date. The FDA can issue approvals or Complete Response Letters ahead of schedule if the review is completed early.
What happens if FDA misses the PDUFA date?
It is rare but possible. When the FDA anticipates needing more time, they typically communicate an extension before the original PDUFA date, usually pushing it out by 3 months. Missing a PDUFA date without prior notice is extremely uncommon and would be considered a serious regulatory failure.
How often do PDUFA decisions result in approval?
Historically, approximately 68% of NDA (New Drug Application) and BLA (Biologics License Application) decisions result in approval. However, approval rates vary significantly by therapeutic area and application type. Rare disease and oncology approvals often have higher success rates, while competitive markets may have lower rates.
Where can I find upcoming PDUFA dates?
PDUFA.bio tracks all upcoming FDA dates with ODIN probability scores. You can browse the 2026 PDUFA calendar to find drugs in your sector of interest, sorted by approval probability and therapeutic area. All upcoming dates are updated regularly as FDA accepts new applications.
Next Steps
- Track Upcoming Dates: Browse the PDUFA calendar 2026 to see which drugs are approaching decision dates.
- Check ODIN Scores: Review ODIN probability estimates for each upcoming PDUFA to identify the highest-conviction opportunities.
- Learn Runup Trading: Study the runup strategy guide to understand how to profit from pre-decision momentum.
- Explore Technical Details: Check our comprehensive glossary for definitions of regulatory terms like NDA, BLA, CRL, and more.